Key facts
- Notable investors include SideCar Angels, Beacon Angels.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for NF2 Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for NF2 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NF2 Therapeutics
Operator of a biotechnology company intended to help patients, physicians, and researchers bring patients safe and effective therapies for NF2 and related disorders. The company focused on the development of therapies for Neurofibromatosis 2 and other disorders, an antibody-drug conjugate for meningiomas in NF2, and gene replacement therapy for vestibular schwannomas, and meningiomas in NF2.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Website
- nf2tx.com/
- Ownership
- Privately Held (backing)
NF2 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NF2 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NF2 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.